Navigation Links
Micell Technologies Announces Presentation of Clinical Data at TCT 2011
Date:11/2/2011

DURHAM, N.C., Nov. 2, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed a preliminary analysis of data from the first-in-human clinical study, DESSOLVE I, of the MiStent® Sirolimus Drug Eluting Coronary Stent System, a thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation that is designed for controlled drug release. Four, six and eight month data will be presented at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2011) in San Francisco, CA.

The presentation will be given in a Scientific Session, "Next Generation Drug-Eluting Stents and Bioabsorbable Scaffolds: Session II - Representative DES with Bioresorbable Polymers," on Tuesday, November 8 at 12:15 p.m. PST. Results will be presented by John Ormiston, M.D., Interventional Cardiologist with the Auckland Heart Group and Medical Director at Mercy Angiography in Auckland, New Zealand. William Wijns, M.D., Interventional Cardiologist with the Cardiovascular Center, Aalst, Belgium, and John Ormiston, M.D. are principal investigators for the study.

In the DESSOLVE I clinical trial, the MiStent DES was used to treat 30 patients with de novo lesions in coronary arteries ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm length stent. The study was performed in five centers in New Zealand, Australia and Belgium. This trial focused on evaluating the efficacy of the MiStent DES, and examined three independent groups of 10 patients using angiography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) at four, six and eight months to evaluate the rate of in-stent late lumen loss (LLL) and the extent of tissue coverage of the stent at each time point.

Micell Technologies currently is conducting a second trial of the MiStent DES, DESSOLVE II; a prospective, single-blind, unbalanced randomized, controlled, multicenter superiority trial in Europe, Australia and New Zealand. This trial completed enrollment in July 2011 with 183 patients enrolled.

About the MiStent DES

The MiStent Sirolimus Eluting Coronary Stent System is designed to optimize healing in patients with coronary artery disease. Micell's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and polymer exposure duration to reduce the safety risks associated with current commercially available drug-eluting stent technologies.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent DES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility. GLP pre-clinical trials have shown that the drug/polymer coating is eliminated from the MiStent DES within 45 to 60 days. In addition, the polymer-based coating is fully absorbed in tissue by 90 days in vivo, at which point the bare-metal stent remains. The MiStent DES is being evaluated in international clinical studies and patient enrollment is complete in those studies.

The MiStent Sirolimus Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

About Micell Technologies Inc.

Micell Technologies® is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns associated with currently available drug-eluting stents. Micell also is developing a drug-coated balloon for vascular interventions. Visit us at www.micell.com.

Micell, Micell Technologies, the Micell Logo, and MiStent are among the registered trademarks of Micell Technologies, Inc.

Contact: Micell Technologies
Arthur J. Benvenuto, Chairman & CEO
(919) 313-2104


'/>"/>
SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
2. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
3. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
8. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
9. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... The Board of Directors of Nordic ... 2016 including the complete 2016 Annual Accounts with notes. The ... Nanovector,s website in the section Investor Relations/Reports and presentations/Annual Reports. ... For ... Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... Devices Market: Analysis By Procedure, Replacement Procedure By Technique, Repair Procedure ... offering. ... Heart Valve Devices Market is forecasted to grow at a CAGR ... valve devices is driven by rising aging population, growth in population ...
(Date:3/23/2017)... As a result of diagnostic technology ... of allergic diseases, cutting edge developments in targeted ... ways in which pharmaceutical and biotech companies are ... be both a high quality meeting and a ... immunologists, research scholars and doctors. The event will ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... 2017 , ... Judy Buchanan, co-owner of Serenity Natural Health ... says, “I am passionate about sharing Reiki as a holistic, complementary therapy with ... time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical Reiki™ ...
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The ... about real people of God in congregations across the United States. “The ... minister ordained in 1964 who has served congregations in seven states throughout his ...
Breaking Medicine News(10 mins):